Prosecution Insights
Last updated: July 17, 2026
Application No. 18/572,110

Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors

Non-Final OA §102
Filed
Dec 19, 2023
Priority
Jul 02, 2021 — provisional 63/218,090 +1 more
Examiner
INAM, SAHAR
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Mirati Therapeutics Inc.
OA Round
1 (Non-Final)
100%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 100% — above average
100%
Career Allowance Rate
1 granted / 1 resolved
+40.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
16 currently pending
Career history
11
Total Applications
across all art units

Statute-Specific Performance

§103
86.2%
+46.2% vs TC avg
§102
13.8%
-26.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of Group I (i.e., claims 1-2, 4-6, 8-17 and 19-20) in the reply filed on 4/24/2026 is acknowledged. Applicants amended of claims 2, 4-6, 8-15, 20-22, 25 and 27 is acknowledged. Applicant’s cancellation of claims 3, 7, 18, 23, 24, and 26 is acknowledged. There are no new claims. Furthermore, applicant’s election of the following species “14-2” for Group I PNG media_image1.png 120 172 media_image1.png Greyscale without traverse is acknowledged. Since, the applicant elected group I (i.e., claims 1-2, 4-6, 8-17 and 19-20), therefore, based on that election, claims 21, 22, 25, and 27 are withdrawn as being drawn to a non-elected group. Claims 1-2, 4-6, 8-17, and 19-20 are under consideration in this office action and will be examined on the merits. Status of Claims Claims 1-2,4-6,8-17,19-22,25 and 27are pending. The preliminary amendment was filed on 12/19/2023, wherein the applicant amended claims 2, 4-6, 8-15, 20-22, 25 and 27, and canceled claims 3, 7, 18, 23, 24, and 26. There are no new claims. Claims 1-2, 4-6,8 -17 and 19-20 are under consideration in the instant office action. Information Disclosure Statement The information disclosure statement (IDS) submitted on 12/19/2023 and 4/15/2024 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-2, 4-6, 8 -17 and 19-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Zhang et al. (“Computational study of the substituent effect of halogenated fused-ring heteroaromatics on halogen bonding” Journal of Molecular Modeling (2020) 26: 270) herein referred to as Zhang. Regarding claims 1-2, 4-6, 8 -17 and 19-20, Zhang teaches halogenated fused-ring heteroaromatics similar to the compounds of Formula I. PNG media_image2.png 818 748 media_image2.png Greyscale Zhang teaches structures of the halogen bond formed by the halogenated 1H-pyrrolo[3,2-b]pyridine derivatives and ammonia (X = Br, I) as depicted on page: 2 (Fig. 1) and below: PNG media_image3.png 164 576 media_image3.png Greyscale wherein; R1 in the instant formula I PNG media_image4.png 116 170 media_image4.png Greyscale is Br; R2 is CH3 (C1-C2 alkyl); A in the instant formula I PNG media_image5.png 130 120 media_image5.png Greyscale is PNG media_image6.png 92 60 media_image6.png Greyscale ; wherein; R4 is hydrogen; R13 is hydrogen; and R14 is hydrogen. The scope of Zhang’s compounds overlaps with Formula I of the instant claims. Based on the foregoing reasons, the instant claims are deemed anticipated over the cited art. Conclusion Claims 1-2, 4-6,8 -17 and 19-20 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SAHAR INAM whose telephone number is (571)272-0821. The examiner can normally be reached 7:30 am-5:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SAHAR INAM/ Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/ Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Dec 19, 2023
Application Filed
Jun 12, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12642808
METHODS OF INHIBITING KLEBSIELLA PNEUMONIAE CARBAPENEMASE-2
2y 8m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
100%
Grant Probability
99%
With Interview (+0.0%)
2y 5m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month